Pathologist Validation of a Machine Learning–Derived Feature for Colon Cancer Risk Stratification

Key Points Question Can a prognostic machine learning–derived histopathologic feature be learned and validated by pathologists? Findings In this prognostic study, 2 pathologists were able to learn a machine learning–derived histopathologic feature and validate its prognostic value for survival among patients with colon cancer. Meaning These findings suggest that computationally identified histopathologic features can provide prognostic value for colon cancer, with the potential for integration into pathology practice.

[1]  Jakob Nikolas Kather,et al.  Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer , 2021, The Journal of pathology.

[2]  M. Todaro,et al.  Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery , 2021, Nature Communications.

[3]  Ellery Wulczyn,et al.  Interpretable survival prediction for colorectal cancer using deep learning , 2020, npj Digital Medicine.

[4]  Marco Novelli,et al.  Deep learning for prediction of colorectal cancer outcome: a discovery and validation study , 2020, The Lancet.

[5]  A. Madabhushi,et al.  Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology , 2019, Nature Reviews Clinical Oncology.

[6]  Georg Langs,et al.  Causability and explainability of artificial intelligence in medicine , 2019, WIREs Data Mining Knowl. Discov..

[7]  F. Galuppini,et al.  Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. , 2019, Human pathology.

[8]  T. Schaller,et al.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance? , 2018, Virchows Archiv.

[9]  S. Homer-Vanniasinkam,et al.  Role of tissue microenvironment resident adipocytes in colon cancer , 2017, World journal of gastroenterology.

[10]  Joseph Kannarkatt,et al.  Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. , 2017, Journal of oncology practice.

[11]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[12]  R. Riddell,et al.  Optimizing the Detection of Venous Invasion in Colorectal Cancer: The Ontario, Canada, Experience and Beyond , 2014, Front. Oncol..

[13]  Cord Langner,et al.  Cancer Management and Research Dovepress Prognostic Stratification of Colorectal Cancer Patients: Current Perspectives , 2022 .

[14]  Viktor H. Koelzer,et al.  The Tumor Border Configuration of Colorectal Cancer as a Histomorphological Prognostic Indicator , 2014, Front. Oncol..

[15]  R. Riddell,et al.  Tumor budding in colorectal carcinoma: time to take notice , 2012, Modern Pathology.

[16]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Giacomo Puppa,et al.  TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. , 2010, Archives of pathology & laboratory medicine.

[18]  M. Washington,et al.  Lymphovascular Invasion in Colorectal Cancer: An Interobserver Variability Study , 2008, The American journal of surgical pathology.

[19]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.